Gastric Recalibration After Endoscopic Sleeve Gastroplasty
ConditionMorbid Obesity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorIHU Strasbourg
About this trial
Endoscopic sleeve gastroplasty (ESG) is a technique used for bariatric surgery, with results comparable to conventional surgery, in order to treat morbid obesity. It has also less risks of complications, and it is not an irreversible technique. It can be repeated overtime, regarding the evolution of the gastroplasty. There is little data in the literature on the effectiveness of endoscopic "revision". This study will assess the benefits and costs of a revision during the follow-up endoscopy.
Eligibility criteria
Qualifiers
Patients aged 18 to 75
Patients with morbid obesity (BMI≥ 30 with comorbidities or> 40)
Patients with obesity for more than 2 years
Failure of medical treatment of obesity
Disqualifiers
Patient with a contraindication to perform an ESG
Patient with a history of previous bariatric, gastric or esophageal surgery.
Patient who initiated medical therapy within the last 3 months, with evidence of weight gain.
Patient with an uncontrolled, poorly controlled, or suspected history of eating disorders or psychiatric illness.
Trial design
Treatments tested in this trial
- Endoscopic placement of additional sutures
Treatment groups
100 Participants
are divided into 2 treatment groupsLocations
1Service de chirurgie digestive et endocrinienne, NHC67000, Strasbourg France
Sponsors and collaborators
IHU Strasbourg
Lead sponsor
Source ClinicalTrials.gov